Kitsa: the clinical research network connecting trial sponsors and research sites

When your Phase III protocol needs a substantial amendment, the median direct cost is $535,000. For Phase II, it's $141,000. These aren't rare events: 76% of protocols now require at least one substantial amendment, with an average of 3.3 amendments per protocol. What's more striking is that roughly 45% of those amendments were classified as avoidable by the sponsors themselves.

Many avoidable amendments stem from document-quality failures: conflicting eligibility criteria between the protocol and Statistical Analysis Plan, inconsistent specifications across the protocol and Informed Consent Form, or protocol design flaws that prove operationally unworkable at sites. These errors typically cost $50 to $80 per hour to create, but the downstream consequences, extending trial timelines by an average of three unplanned months, can add roughly $3.6 million in direct operational costs.

Protocol complexity compounds the problem. Since 2005, procedures per protocol have increased 139%, endpoints have grown 214%, and data points collected have risen 600%. Each addition creates documentation obligations across multiple documents that must remain internally consistent. Manual writing processes don't scale proportionally with this complexity. A single specification mismatch between documents can generate protocol deviations, regulatory queries, o

Switzerland is a small market by population, but one of the most concentrated pharmaceutical and clinical research ecosystems in the world.

With 8.9 million people, a nationally coordinated network of seven Clinical Trial Units and major research hubs across Basel, Zurich, Lausanne, Geneva and Bern, Switzerland offers sponsors access to experienced investigators, specialist academic centres and highly structured trial infrastructure.

Its biggest advantage is not patient volume. It is research quality and concentration.

Basel alone brings together Roche, Novartis and more than 800 life sciences companies, while ETH Zurich, EPFL and major university hospitals support strong translational research across oncology, immunology, rare disease, neuroscience, precision medicine and advanced therapies.

For sponsors, the value is particularly strong in early phase and scientifically complex programs. Parallel Swissmedic and ethics review, ICH aligned regulatory standards, nationally coordinated CTUs and close proximity between academic medicine and global pharma can support tighter investigator collaboration, high quality data generation and efficient multi centre execution.

Switzerland is therefore especially relevant when a program needs scientific credibility, specialist investigators, early phase expertise and a

Informed consent failures appeared across multiple categories of FDA's 1,073 BIMO inspections in FY2023, from missing IRB-required addenda to collecting samples from subjects who explicitly refused consent. The root cause is treating the ICF as a one-time checkbox instead of an ongoing process. FDA guidance is clear: informed consent doesn't end at signature. Sites must update forms when new safety data emerges, initiate re-consent after protocol amendments that change risk profiles, and maintain rigorous version control. Your template must cover 21 CFR 50.25's eight basic elements plus applicable additional elements, align with ICH E6(R3)'s risk-proportionate approach, and increasingly include a key information section up front. Templates that fail to make re-consent obligations visible create downstream compliance risk. The document a subject takes home is both a reference tool and a living record of what was communicated throughout their participation.

Roughly 90% of clinical trial protocols still exist as unstructured Word documents, according to TransCelerate BioPharma's October 2025 update. The Schedule of Activities sits at the center of that problem: a table full of merged cells, footnotes, and conditional logic that humans read easily but computers cannot parse reliably. Every protocol amendment that changes a visit window or procedure triggers manual re-keying into EDC, CTMS, and SDTM systems, turning a single change into weeks of downstream rework.

The Unified Study Definitions Model, or USDM, is the CDISC standard built to fix that. Instead of a static table, USDM represents the schedule as linked data: timepoints, activities, and conditions that software can read, validate, and propagate automatically. A recent analysis found protocols now average 3.3 amendments each, with a single Phase III amendment costing a median $535,000 to implement over 260 days. USDM does not eliminate amendments, but it removes the re-transcription step that makes each one expensive.

CDISC released USDM version 4.0 in June 2025, and the FDA finalized its ICH M11 protocol guidance in May 2026. The two standards are aligned but distinct: M11 governs the protocol document structure, while USDM governs the underlying study design data. For site coordinators, the practical difference shows up as consistent, system-generated visi

Belgium combines a relatively small population with unusually high clinical research density.

With 11.6 million people, 474 clinical trial authorizations recorded in 2022 and a long standing position among Europe’s leading markets for trials per capita, Belgium has built a research ecosystem that is significantly larger than its geographic size would suggest.

Its strongest advantage is concentration. Seven university hospitals, major academic centres across Leuven, Ghent, Brussels, Liège and Antwerp, and 135 active CROs give sponsors access to experienced investigators and operational partners within a compact national footprint.

Belgium is particularly strong in Phase I and first in human research, alongside oncology, rare disease, cardiovascular research, neurology, paediatrics, immunology and advanced therapies.

For sponsors, this creates a practical advantage. Early phase expertise, established university hospital relationships, EU CTR alignment and short distances between major research centres can make Belgium useful for programs that require specialist investigators, intensive site oversight and coordinated European execution.

Clinical regulatory writing produces the structured documents health authorities require to evaluate and approve pharmaceutical products. These aren't neutral scientific papers but compliance-focused submissions for FDA, EMA, and other regulators. The work spans protocols, Clinical Study Reports, Investigator's Brochures, informed consent forms, and marketing applications. Quality matters: analysis of 836 protocols found that 57% undergo substantial amendments, with approximately 45% of those classified as avoidable, often due to eligibility criteria or design inconsistencies not fully resolved before finalization. More recent data shows Phase III protocols now average 3.5 substantial amendments, up nearly 60% since 2015. Between 2018 and 2022, 37% of all NDAs and BLAs received Complete Response Letters. ICH E6(R3), finalized in January 2025 and effective in the EU as of July 2025, now emphasizes Quality Management Systems and risk-based approaches. For sites, this means documentation must reflect quality-by-design thinking, with risk assessments and quality tolerance limits visible in trial documents, not buried in operational procedures.

Large language models write fluent regulatory text, but they fail on the dimension that matters most: clinical logic aligned with current guidance. A 2025 study testing LLM-generated protocols found over 80% content relevance but only 40% accuracy on clinical thinking and logic, the measure of whether recommendations follow sound trial design and regulatory standards. Retrieval-augmented generation (RAG) fixes this by pulling relevant guidance documents into the model's context at generation time, rather than relying on outdated training data. The same study found RAG substantially improved clinical thinking scores, with the largest gains in the exact area where base models struggled.

RAG systems retrieve chunks from curated document libraries (FDA guidance, ICH standards, prior protocols, internal SOPs) and condition the model's output on those sources. Every substantive statement can trace back to a retrieved passage, making citations verifiable instead of fabricated. This matters for compliance: ICH E3 requires Clinical Study Reports to reflect the protocol exactly, and discrepancies between documents trigger regulatory questions. RAG architectures can ground all outputs in the same corpus throughout the writing process, reducing cross-document inconsistency.

Retrieval quality determines performance. Hybrid methods combining dense vector search with key

In November 2025, ICH endorsed M11, the first internationally harmonized clinical trial protocol template. The FDA finalized guidance in May 2026, and the EMA adopted it in December 2025. But M11 only defines what protocol content should contain, not how software systems can actually use it. That's where CDISC's Unified Study Definitions Model (USDM) comes in. USDM turns M11's structured content into a machine-readable data model that EDC systems, CTMS platforms, and registry submissions can consume directly.

Right now, roughly 90% of protocols still exist only as unstructured text, according to TransCelerate. That means every downstream system gets built by someone reading the protocol document and re-entering content by hand. The average lag between protocol approval and study start is four months, largely due to this manual work. When amendments happen, and 57% of trials have at least one substantial amendment, the cycle repeats. A 2016 Tufts analysis found the median direct cost of a Phase III amendment was over half a million dollars, not counting delayed enrollment.

For sites, USDM won't eliminate amendments or complexity. But once your sponsor's systems integrate with it, protocol changes should cascade automatically to your EDC, informed consent forms, and training materials instead of requiring fresh manual updates every time.

Using artificial intelligence (AI) in research offers many important benefits for science and society but also creates novel and complex ethical issues. While these ethical issues do not necessitate changing established ethical norms of science, they require the scientific community to develop new guidance for the appropriate use of AI. In this article, we briefly introduce AI and explain how it can be used in research, examine some of the ethical issues raised when using it, and offer nine recommendations for responsible use, including: (1) Researchers are responsible for identifying, describing, reducing, and controlling AI-related biases and random errors; (2) Researchers should disclose, describe, and explain their use of AI in research, including its limitations, in language that can be understood by non-experts; (3) Researchers should engage with impacted communities, populations, and other stakeholders concerning the use of AI in research to obtain their advice and assistance and address their interests and concerns, such as issues related to bias; (4) Researchers who use synthetic data should (a) indicate which parts of the data are synthetic; (b) clearly label the synthetic data; (c) describe how the data were generated; and (d) explain how and why the data were used; (5) AI systems should not be named as authors, inventors, or copyright holders but their contributions to research should be disclosed and described; (6) Education and mentoring in responsible conduct o

The average protocol now carries 3.3 amendments before completion, up 60% from pre-2015 levels. Each amendment triggers a cascade: revised protocol, updated ICF, amended Investigator's Brochure, sometimes a DSUR. Implementing one amendment takes an average of 260 days from identification to final IRB approval. Traditional medical writing outsourcing, built around word processors and email threads, hasn't scaled with this burden. The model still delivers real value for specialized therapeutic area expertise and flexible capacity, but four structural weaknesses now limit its effectiveness: writer availability determines document timing, with 25% of job postings unfilled for over three months; turnaround time between database lock and submission-ready CSR can delay regulatory filings by three to six months; cross-document consistency failures create compliance gaps that regulators flag as submission errors; and amendment cascades require separate engagements for each dependent document, creating natural version drift. AI-native tools change this calculus. Merck's generative AI platform cut CSR first draft production from 180 to 80 human-review hours while reducing errors by 50%, freeing medical writers to focus on interpretive work that requires clinical judgment rather than structured data extraction and terminology checking.